Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECT-5: 52-week open-label extension of rosiglitazone XR in mild-to-moderate Alzheimer's disease
2006-005078-28Phase 3Terminated
- Sponsor
- GSK
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Primary endpoint: Incidence and severity of adverse events. Started Jul 2007; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-005078-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005078-28.